Search

Your search keyword '"Orlando, Bianca"' showing total 19 results
Start Over Author "Orlando, Bianca"
19 results on '"Orlando, Bianca"'

1. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Author

Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola

Published
2024
Full Text
View/download PDF

3. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

4. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Author

Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola

Published
2024
Full Text
View/download PDF

5. Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

10. List of contributors

Author

Alekhina, Iuliia, primary, Amirov, Abdulkarim, additional, Anisimov, Nikolay V., additional, Blanco, Juan Maria, additional, Cabal-Mirabal, Carlos, additional, Chacon-Caldera, Jorge, additional, Charreyron, Samuel L., additional, Choi, Seung-Bok, additional, Corte-Leon, Paula, additional, Cotelli, Maria, additional, Dee, Garret, additional, Duan, Xiaodong, additional, Ferreri, Florinda, additional, Franke, Jochen, additional, Gervits, Lev L., additional, Gulyaev, Mikhail V., additional, Gun’ko, Yurii K., additional, Gurfinkel, Yury I., additional, Hilger, Ingrid, additional, Iodice, Francesco, additional, Ipatov, Mihail, additional, Judica, Elda, additional, Komlev, Aleksei S., additional, Kramarenko, Elena, additional, Kritskiy, Alexander, additional, Lomova, Maria V., additional, Makarova, Liudmila, additional, Maslennikov, Yuri, additional, Meersmann, Thomas, additional, Miraglia, Francesca, additional, Mushnikov, Nikolay V., additional, Naumova, Anna V., additional, Nelson, Bradley J., additional, Nguyen, Nam-Trung, additional, Oh, Jong-Seok, additional, Orlando, Bianca, additional, Pavlova, Olga S., additional, Pavlovskaya, Galina E., additional, Perov, Nikolai, additional, Pirogov, Yury A., additional, Pishchalnikov, Roman Y., additional, Pyatakov, Alexander, additional, Pyatakova, Zoya, additional, Rossini, Paolo Maria, additional, Sadykhov, Elnur, additional, Semenova, Natalia, additional, Singh, Gurjit, additional, Sukhorukov, Gleb B., additional, Tishin, Alexander M., additional, Vecchio, Fabrizio, additional, Volkov, Dmitry V., additional, Zhang, Jun, additional, Zhukov, Arcady, additional, Zhukova, Valentina, additional, and Zverev, Vladimir I., additional

Published
2022
Full Text
View/download PDF

11. Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.

Author

Orlando, Bianca, Egeo, Gabriella, Aurilia, Cinzia, Fiorentini, Giulia, and Barbanti, Piero

Subjects
*CALCITONIN gene-related peptide, *ERENUMAB, *MIGRAINE, *TREATMENT effectiveness, *DATA extraction
Abstract

Background: The advent of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has transformed the management of migraine, offering newfound optimism for clinicians and individuals with episodic migraine (EM) and chronic migraine (CM). While randomized controlled trials (RCTs) have provided crucial insights into the effectiveness and safety profiles of these treatments, their translation into real-world clinical practice remains a challenge. Objective: This review aims to conduct a comprehensive assessment of real-world studies, offering valuable insights tailored for practical application in clinical settings. Methods: We conducted a comprehensive literature search in PubMed, SCOPUS, and MEDLINE for real-life studies on erenumab, fremanezumab, and galcanezumab. Abstracts underwent rigorous screening by two reviewers for relevance. Data extraction from selected articles was performed using a standardized form, with verification by a second reviewer. Data synthesis was narrative, following PRISMA guidelines. Results: Our search included 61 pertinent studies conducted between 2019 and 1 March 2024. Real-world study designs demonstrated notable variability in the selection and inclusion of migraine patients, influenced by factors such as attack frequency, data collection criteria, and primary/secondary objectives. Key findings commonly reported considerable improvements in efficacy outcomes (migraine frequency, analgesic use, pain severity, and disability), high responder rates, and optimal safety and tolerability profiles. Conclusions: Real-world evidence underscores the role of anti-CGRP mAbs as targeted therapies for both CM and EM patients. The overall results indicate that the effectiveness and tolerability of anti-CGRP mAbs in real-world applications may exceed those observed in RCTs, an extraordinary finding in clinical neurology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study.

Author

Barbanti, Piero, Orlando, Bianca, Egeo, Gabriella, d'Onofrio, Florindo, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Messina, Roberta, Filippi, Massimo, Fiorentini, Giulia, Rotondi, Cristina, Bonassi, Stefano, and Aurilia, Cinzia

Subjects
*IMPACT testing, *MIGRAINE, *PEPTIDES, *TREATMENT failure, *CONTENT analysis
Abstract

We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-frequency episodic migraine (HFEM) or chronic migraine (CM). The primary endpoint was the change in monthly migraine days (MMD) for HFEM or monthly headache days (MHD) for CM at weeks 9–12 compared to baseline. The secondary endpoints included changes in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), Migraine Disability Assessment Scale (MIDAS), Migraine Interictal Burden Scale (MIBS-4), and responder rates. The safety analysis involved 44 subjects; the effectiveness analysis included 26 individuals. Eptinezumab was well-tolerated. In CM patients, eptinezumab significantly reduced MHD (−16.1 ± 9.9, p < 0.001), MAI, NRS, HIT-6, MIDAS, and MIBS-4. In HFEM patients, it significantly reduced NRS, HIT-6, MIDAS, and MIBS-4, though reductions in MMD (−3.3 ± 4.5) and MAI were not statistically significant. Overall, ≥50% and ≥75% response rates were 61.5% and 30.8%, respectively (60% and 30% in non-responders to subcutaneous anti-CGRP mAbs). The clinical change was rated as much or very much improved by 61.0% of the patients. Eptinezumab demonstrated high effectiveness, safety, and tolerability in real-life among hard-to-treat migraine patients with multiple treatment failures, including anti-CGRP mAbs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Evidence-Based Checklist for Organ Donor Management – A Cluster-Randomized Trial

Author

Westphal, Glauco Adrieno, primary, Robinson, Caroline Cabral, additional, Giordani, Natalia Elis, additional, Teixeira, Cassiano, additional, Rohden, Adriane Isabel, additional, Gimenes, Bruna dos Passos, additional, Guterres, Cátia Moreira, additional, Madalena, Itiana Cardoso, additional, Andrighetto, Luiza Vitelo, additional, da Silva, Sabrina Souza, additional, da Silva, Daiana Barbosa, additional, Sganzerla, Daniel, additional, Cavalcanti, Alexandre Biasi, additional, Franke, Cristiano Augusto, additional, Bozza, Fernando A., additional, Machado, Flávia Ribeiro, additional, de Andrade, Joel, additional, Azevedo, Luciano Cesar Pontes, additional, Schneider, Silvana, additional, Orlando, Bianca Rodrigues, additional, Grion, Cintia Magalhães Carvalho, additional, Bezerra, Fernando Albuerne, additional, Roman, Fernando Roberto, additional, Leite Júnior, Francisco Olon, additional, Siqueira, Íris de Lima Ferraz, additional, Oliveira, João Fernando Picollo, additional, de Oliveira Júnior, Lúcio Couto, additional, de Melo, Maria de Fátima Rodrigues Bua, additional, Leal, Patrícia Berg Gonçalves Perei, additional, Diniz, Pedro Carvalho, additional, Moraes, Rafael Barberena, additional, Pontes, Daniela Ferreira Salomão, additional, Queiroz, Joselio Emar de Araujo, additional, Hammes, Luciano Serpa, additional, Meade, Maureen, additional, Rosa, Regis Goulart, additional, and Falavigna, Maicon, additional

Published
2021
Full Text
View/download PDF

16. Evidence-Based Checklist to Delay Cardiac Arrest in Brain-Dead Potential Organ Donors: The DONORS Cluster Randomized Clinical Trial.

Author

Westphal, Glauco A., Robinson, Caroline Cabral, Giordani, Natalia Elis, Teixeira, Cassiano, Rohden, Adriane Isabel, dos Passos Gimenes, Bruna, Guterres, Cátia Moreira, Madalena, Itiana Cardoso, Andrighetto, Luiza Vitelo, Souza da Silva, Sabrina, Barbosa da Silva, Daiana, Sganzerla, Daniel, Cavalcanti, Alexandre Biasi, Franke, Cristiano Augusto, Bozza, Fernando Augusto, Machado, Flávia Ribeiro, de Andrade, Joel, Pontes Azevedo, Luciano Cesar, Schneider, Silvana, and Orlando, Bianca Rodrigues

Published
2023
Full Text
View/download PDF

18. Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial)

Author

Correa Barcellos, Franklin, primary, Pereira Nunes, Bruno, additional, Jorge Valle, Luciana, additional, Lopes, Thiago, additional, Orlando, Bianca, additional, Scherer, Cintia, additional, Nunes, Marcia, additional, Araújo Duarte, Gabriela, additional, and Böhlke, Maristela, additional

Published
2016
Full Text
View/download PDF

19. Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic

Author

Gianmarco Abbadessa, Francesco Iodice, Bianca Orlando, Giovanni Cirillo, Simona Bonavita, Giuseppina Miele, Marinella Clerico, Francesca Trojsi, Luigi Lavorgna, Marco Bozzali, Silvia Casagrande, Letizia Leocani, Gioacchino Tedeschi, Dario Ricciardi, Ricciardi, Dario, Casagrande, Silvia, Iodice, Francesco, Orlando, Bianca, Trojsi, Francesca, Cirillo, Giovanni, Clerico, Marinella, Bozzali, Marco, Leocani, Letizia, Abbadessa, Gianmarco, Miele, Giuseppina, Tedeschi, Gioacchino, Bonavita, Simona, Lavorgna, Luigi, Ricciardi, D., Casagrande, S., Iodice, F., Orlando, B., Trojsi, F., Cirillo, G., Clerico, M., Bozzali, M., Leocani, L., Abbadessa, G., Miele, G., Tedeschi, G., Bonavita, S., and Lavorgna, L.

Subjects
medicine.medical_specialty, Telemedicine, Neurology, Coronavirus disease 2019 (COVID-19), Myasthenia gravi, Dermatology, Disease, Tele-health, Pandemic, Myasthenia Gravis, medicine, Humans, Intensive care medicine, Adverse effect, Myasthenia gravis, Pandemics, business.industry, SARS-CoV-2, COVID-19, General Medicine, medicine.disease, Psychiatry and Mental health, Neurology (clinical), Neurosurgery, Tele-neurology, business
Abstract

COVID-19 pandemic has induced an urgent reorganization of the healthcare system to ensure continuity of care for patients affected by chronic neurological diseases including myasthenia gravis (MG). Due to the fluctuating nature of the disease, early detection of disease worsening, adverse events, and possibly life-threatening complications is mandatory. This work analyzes the main unresolved issues in the management of the myasthenic patient, the possibilities offered so far by digital technologies, and proposes an online evaluation protocol based on 4 simple tests to improve MG management. Telemedicine and Digital Technology might help neurologists in the clinical decision-making process of MG management, avoiding unnecessary in presence consultations and allowing a rational use of the time and space reduced by the pandemic.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results